BETA
Your AI-Trained Oncology Knowledge Connection!
Role for Transplantation and Maintenance Therapy in NDMM
Considerations for assessing eligibility of patients for transplantation for NDMM and how maintenance therapy may be initiated in the post-transplant setting.
Patient Characteristics in ELEVATE-RR
Dr Bishop comments on the characteristics of the patients with CLL who were enrolled in the ELEVATE-RR trial.
Uday R. Popat, MD, on Post-Transplant Cyclophosphamide Following Myeloablative Busulfan as GVHD Prophylaxis
Uday R. Popat, MD, spoke about how use of post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease following matched donor hematopoietic cell transplantation for acute myeloid leukemia could impact the standard of care.
Role of Neurooncologists in Management of HER2+ Breast Cancer and Brain Metastases
A look at the evolving role of neurooncologists in the treatment of patients with HER2+ breast cancer and brain metastases and future perspectives in the management of this patient population.
A Pediatric Regimen for Older Adults and Adolescents with ALL: CALGB 10403 Study
Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.
ASCO GU 2022 Updates: Antibody-Drug Conjugates
Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.
Trastuzumab Deruxtecan Treatment for Metastatic HER2+ Breast Cancer with Brain Metastases
Experts have a conversation of the use of trastuzumab deruxtecan therapy for patients with progressive brain metastases while weighing common toxicities and clinical trial data.
ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy
Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.
Cross Q&A: Team Moffitt Marrowvingians
The Memorial Sloan Kettering team gets the opportunity to question the clinical trial data presented by the H. Lee Moffitt team.
Higher-Risk MDS Satellite Symposium
Program chair Navel Daver, MD, invites you to PER®’s complimentary in-person and virtual satellite symposium.
Next-Gen SERDs in ER+/HER- Breast Cancer Satellite Symposium
Program chair Aditya Bardia, MD, MPH, invites you to PER®’s complimentary in-person and virtual satellite symposium.
Patient Profile 2: EGFR Exon 19 Deletion–Positive NSCLC
Shared insight on the diagnosis and management of EGFR exon 19 deletion–positive NSCLC, with regard for the potential of osimertinib in this setting.
NSCLC: Selecting Therapy Based on PD-L1 Status and Staging
A brief review of how treatment may be selected for a patient with NSCLC based on their PD-L1 expression and disease staging.
Mark T. Fleming, MD, Talks Use of 18F-rhPSMA-7.3 for PET/CT in Recurrent Prostate Cancer
Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.
Transplant-Ineligible Multiple Myeloma: The SWOG0777 Study
Nisha Joseph, MD, presents the case of a 78-year-old man with transplant-ineligible multiple myeloma and discusses treatment strategy.
Defining High-Risk Multiple Myeloma
Experts discuss how they define frail and high-risk patients with multiple myeloma and their treatment approaches for these patient populations.
GALAXY: DFS by Stage and ACT Receipt in ctDNA-Positive Patients
Stacy A. Cohen, MD, and Mark Lewis, MD, discuss how DFS correlates with stage and adjuvant chemotherapy receipt in patients who are ctDNA-positive.
Choosing Therapies for Patients with Advanced Renal Cell Carcinoma
A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.
GALAXY: DFS by ctDNA Status at Weeks 4 and 12 Post Surgery
GI oncologists discuss DFS data from the dynamics analysis cohort of the GALAXY study.
Perspectives on COVID-19 Prophylaxis and Vaccination
To close the discussion, panelists reflect on their practices’ guidance on long-acting antibody prophylaxis and vaccination against COVID-19 for patients with graft-versus-host-disease (GVHD).